Characteristics of patients with ENKTL according to chemotherapy regimen
| Characteristics . | Training (N = 399) . | Validation (N = 253) . | ||||||
|---|---|---|---|---|---|---|---|---|
| Total . | S-ID-MTX . | Total . | S-ID-MTX . | |||||
| Yes (n = 100) . | No (n = 299) . | P . | Yes (n = 29) . | No (n = 224) . | P . | |||
| Age (y) | ||||||||
| >60 | 108 (27) | 24 (24) | 84 (28) | .425 | 94 (37) | 13 (45) | 81 (36) | .416 |
| ≤60 | 291 (73) | 76 (76) | 215 (72) | 159 (63) | 16 (55) | 143 (64) | ||
| Sex | ||||||||
| Male | 249 (62) | 67 (67) | 182 (61) | .273 | 173 (68) | 13 (45) | 160 (71) | .006 |
| Female | 150 (38) | 33 (33) | 117 (39) | 80 (32) | 16 (55) | 64 (29) | ||
| ECOG PS | ||||||||
| 0-1 | 340 (85) | 74 (74) | 266 (89) | .001 | 213 (84) | 22 (76) | 191 (85) | .186 |
| 2-4 | 59 (15) | 26 (26) | 33 (11) | 40 (16) | 7 (24) | 33 (15) | ||
| B symptom | ||||||||
| Yes | 133 (33) | 56 (56) | 77 (26) | .001 | 103 (41) | 16 (55) | 87 (39) | .159 |
| No | 266 (67) | 44 (44) | 222 (74) | 145 (57) | 13 (45) | 132 (59) | ||
| NA | 0 (0) | 0 (0) | 0 (0) | 5 (2) | 0 (0) | 5 (2) | ||
| BM involvement | ||||||||
| Yes | 60 (15) | 28 (28) | 32 (11) | .001 | 19 (8) | 8 (28) | 11 (5) | .001 |
| No | 339 (85) | 72 (72) | 267 (89) | 234 (92) | 21 (72) | 213 (95) | ||
| LDH | ||||||||
| Elevated | 180 (45) | 66 (66) | 114 (38) | .001 | 100 (40) | 18 (62) | 82 (37) | .014 |
| Normal | 219 (55) | 34 (34) | 185 (62) | 153 (60) | 11 (38) | 142 (63) | ||
| EBV DNA | ||||||||
| Positive | 224 (56) | 63 (63) | 161 (54) | .166 | 69 (27) | 14 (48) | 55 (25) | .259 |
| Negative | 160 (40) | 35 (35) | 125 (42) | 30 (12) | 3 (10) | 27 (12) | ||
| NA | 15 (4) | 2 (2) | 13 (4) | 154 (61) | 12 (41) | 142 (63) | ||
| Extranodal involvement | ||||||||
| ≥2 | 108 (27) | 33 (33) | 75 (25) | .123 | 64 (25) | 20 (69) | 44 (20) | .001 |
| <2 | 291 (73) | 67 (67) | 224 (75) | 189 (75) | 9 (31) | 180 (80) | ||
| Distant LN involvement | ||||||||
| Yes | 83 (21) | 38 (38) | 45 (15) | .001 | 20 (8) | 8 (28) | 12 (5) | .001 |
| No | 316 (79) | 62 (62) | 254 (85) | 233 (92) | 21 (72) | 212 (95) | ||
| Nonnasal type | ||||||||
| Yes | 64 (16.0) | 35 (35.0) | 29 (9.7) | .001 | 22 (9) | 6 (21) | 16 (7) | .027 |
| No | 335 (84.0) | 65 (65.0) | 270 (90.3) | 231 (91) | 23 (79) | 208 (93) | ||
| Ann Arbor stage | ||||||||
| I/II | 261 (65) | 34 (34) | 227 (76) | .001 | 194 (77) | 5 (17) | 189 (84) | .001 |
| III/IV | 138 (35) | 66 (66) | 72 (24) | 59 (23) | 24 (83) | 35 (16) | ||
| IPI | ||||||||
| Low | 226 (57) | 32 (32) | 194 (65) | .001 | 166 (66) | 6 (21) | 160 (71) | .001 |
| Intermediate | 138 (35) | 52 (52) | 86 (29) | 53 (21) | 13 (45) | 40 (18) | ||
| High | 35 (9) | 16 (16) | 19 (6) | 34 (13) | 10 (34) | 24 (11) | ||
| PINK | ||||||||
| Low | 174 (44) | 18 (18) | 156 (52) | .001 | 124 (49) | 2 (7) | 122 (54) | .001 |
| Intermediate | 116 (29) | 30 (30) | 86 (29) | 80 (32) | 9 (31) | 71 (32) | ||
| High | 109 (27) | 52 (52) | 57 (19) | 49 (19) | 18 (62) | 31 (14) | ||
| CCRT | ||||||||
| Yes | 211 (53) | 18 (18) | 193 (65) | .001 | 177 (70) | 1 (3) | 176 (79) | .001 |
| No | 188 (47) | 82 (82) | 106 (36) | 76 (30) | 28 (97) | 48 (21) | ||
| l-asparaginase | ||||||||
| Yes | 310 (78) | 100 (100) | 210 (70) | .001 | 33 (13) | 29 (100) | 4 (2) | .001 |
| No | 89 (22) | 0 (0) | 89 (30) | 220 (87) | 0 (0) | 220 (98) | ||
| CNS relapse | ||||||||
| Yes | 27 (7) | 5 (5) | 22 (7) | .416 | 18 (7) | 2 (7) | 16 (7) | .99 |
| No | 372 (93) | 95 (95) | 277 (93) | 235 (93) | 27 (93) | 208 (93) | ||
| Relapse type | ||||||||
| Parenchymal | 10 | 3 | 7 | 5 | 0 | 5 | — | |
| Leptomeningeal | 11 | 0 | 11 | 4 | 1 | 3 | ||
| Both | 6 | 2 | 4 | 1 | 0 | 1 | ||
| NA | 0 | 0 | 0 | 8 | 1 | 7 | ||
| Characteristics . | Training (N = 399) . | Validation (N = 253) . | ||||||
|---|---|---|---|---|---|---|---|---|
| Total . | S-ID-MTX . | Total . | S-ID-MTX . | |||||
| Yes (n = 100) . | No (n = 299) . | P . | Yes (n = 29) . | No (n = 224) . | P . | |||
| Age (y) | ||||||||
| >60 | 108 (27) | 24 (24) | 84 (28) | .425 | 94 (37) | 13 (45) | 81 (36) | .416 |
| ≤60 | 291 (73) | 76 (76) | 215 (72) | 159 (63) | 16 (55) | 143 (64) | ||
| Sex | ||||||||
| Male | 249 (62) | 67 (67) | 182 (61) | .273 | 173 (68) | 13 (45) | 160 (71) | .006 |
| Female | 150 (38) | 33 (33) | 117 (39) | 80 (32) | 16 (55) | 64 (29) | ||
| ECOG PS | ||||||||
| 0-1 | 340 (85) | 74 (74) | 266 (89) | .001 | 213 (84) | 22 (76) | 191 (85) | .186 |
| 2-4 | 59 (15) | 26 (26) | 33 (11) | 40 (16) | 7 (24) | 33 (15) | ||
| B symptom | ||||||||
| Yes | 133 (33) | 56 (56) | 77 (26) | .001 | 103 (41) | 16 (55) | 87 (39) | .159 |
| No | 266 (67) | 44 (44) | 222 (74) | 145 (57) | 13 (45) | 132 (59) | ||
| NA | 0 (0) | 0 (0) | 0 (0) | 5 (2) | 0 (0) | 5 (2) | ||
| BM involvement | ||||||||
| Yes | 60 (15) | 28 (28) | 32 (11) | .001 | 19 (8) | 8 (28) | 11 (5) | .001 |
| No | 339 (85) | 72 (72) | 267 (89) | 234 (92) | 21 (72) | 213 (95) | ||
| LDH | ||||||||
| Elevated | 180 (45) | 66 (66) | 114 (38) | .001 | 100 (40) | 18 (62) | 82 (37) | .014 |
| Normal | 219 (55) | 34 (34) | 185 (62) | 153 (60) | 11 (38) | 142 (63) | ||
| EBV DNA | ||||||||
| Positive | 224 (56) | 63 (63) | 161 (54) | .166 | 69 (27) | 14 (48) | 55 (25) | .259 |
| Negative | 160 (40) | 35 (35) | 125 (42) | 30 (12) | 3 (10) | 27 (12) | ||
| NA | 15 (4) | 2 (2) | 13 (4) | 154 (61) | 12 (41) | 142 (63) | ||
| Extranodal involvement | ||||||||
| ≥2 | 108 (27) | 33 (33) | 75 (25) | .123 | 64 (25) | 20 (69) | 44 (20) | .001 |
| <2 | 291 (73) | 67 (67) | 224 (75) | 189 (75) | 9 (31) | 180 (80) | ||
| Distant LN involvement | ||||||||
| Yes | 83 (21) | 38 (38) | 45 (15) | .001 | 20 (8) | 8 (28) | 12 (5) | .001 |
| No | 316 (79) | 62 (62) | 254 (85) | 233 (92) | 21 (72) | 212 (95) | ||
| Nonnasal type | ||||||||
| Yes | 64 (16.0) | 35 (35.0) | 29 (9.7) | .001 | 22 (9) | 6 (21) | 16 (7) | .027 |
| No | 335 (84.0) | 65 (65.0) | 270 (90.3) | 231 (91) | 23 (79) | 208 (93) | ||
| Ann Arbor stage | ||||||||
| I/II | 261 (65) | 34 (34) | 227 (76) | .001 | 194 (77) | 5 (17) | 189 (84) | .001 |
| III/IV | 138 (35) | 66 (66) | 72 (24) | 59 (23) | 24 (83) | 35 (16) | ||
| IPI | ||||||||
| Low | 226 (57) | 32 (32) | 194 (65) | .001 | 166 (66) | 6 (21) | 160 (71) | .001 |
| Intermediate | 138 (35) | 52 (52) | 86 (29) | 53 (21) | 13 (45) | 40 (18) | ||
| High | 35 (9) | 16 (16) | 19 (6) | 34 (13) | 10 (34) | 24 (11) | ||
| PINK | ||||||||
| Low | 174 (44) | 18 (18) | 156 (52) | .001 | 124 (49) | 2 (7) | 122 (54) | .001 |
| Intermediate | 116 (29) | 30 (30) | 86 (29) | 80 (32) | 9 (31) | 71 (32) | ||
| High | 109 (27) | 52 (52) | 57 (19) | 49 (19) | 18 (62) | 31 (14) | ||
| CCRT | ||||||||
| Yes | 211 (53) | 18 (18) | 193 (65) | .001 | 177 (70) | 1 (3) | 176 (79) | .001 |
| No | 188 (47) | 82 (82) | 106 (36) | 76 (30) | 28 (97) | 48 (21) | ||
| l-asparaginase | ||||||||
| Yes | 310 (78) | 100 (100) | 210 (70) | .001 | 33 (13) | 29 (100) | 4 (2) | .001 |
| No | 89 (22) | 0 (0) | 89 (30) | 220 (87) | 0 (0) | 220 (98) | ||
| CNS relapse | ||||||||
| Yes | 27 (7) | 5 (5) | 22 (7) | .416 | 18 (7) | 2 (7) | 16 (7) | .99 |
| No | 372 (93) | 95 (95) | 277 (93) | 235 (93) | 27 (93) | 208 (93) | ||
| Relapse type | ||||||||
| Parenchymal | 10 | 3 | 7 | 5 | 0 | 5 | — | |
| Leptomeningeal | 11 | 0 | 11 | 4 | 1 | 3 | ||
| Both | 6 | 2 | 4 | 1 | 0 | 1 | ||
| NA | 0 | 0 | 0 | 8 | 1 | 7 | ||
S-ID-MTX, SMILE or SMILE-like regimens with intermediate-dose methotrexate; ECOG PS, Eastern Cooperative Oncology Group performance score; BM, bone marrow; NA, not available; LN, lymph node; CCRT, concurrent chemoradiotherapy.